Literature DB >> 21726198

Targeting the regulation of CFTR channels.

Paul D W Eckford1, Christine E Bear.   

Abstract

In this issue of the Biochemical Journal, Zhang et al. reveal a new strategy for modifying the regulated function of CFTR (cystic fibrosis transmembrane conductance regulator) on the apical surface of epithelial cells. Simply stated, these authors tested the idea that the cAMP-dependent channel activity of CFTR could be effectively enhanced by disruption of a protein-protein interaction which is normally inhibitory for the production of cAMP. This particular protein-protein interaction [between the PDZ motif of LPA2 (type 2 lysophosphatidic acid receptor) and the scaffold protein Nherf2 (Na+/H+ exchanger regulatory factor 2)] is localized in the CFTR interactome on the apical membrane of epithelial cells. Hence disruption of the LPA2-Nherf2 interaction should lead to a localized elevation in cAMP and, consequently, increased cAMP-dependent CFTR activity on the surface of epithelial cells. Zhang et al. confirmed these expectations for a small-molecule compound targeting the LPA2-Nherf2 interaction using relevant cultures and tissues thought to model the human respiratory epithelium. The success of this strategy depended on previous knowledge regarding the role for multiple PDZ-motif-mediated interactions in signalling (directly or indirectly) to CFTR. Given the number and diversity of such PDZ-mediated interactions, future structural and computational studies will be essential for guiding the design of specific pharmacological interventions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21726198     DOI: 10.1042/BJ20110461

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  6 in total

Review 1.  Recent advances and new perspectives in targeting CFTR for therapy of cystic fibrosis and enterotoxin-induced secretory diarrheas.

Authors:  Weiqiang Zhang; Naoaki Fujii; Anjaparavanda P Naren
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

2.  CFTR-SLC26 transporter interactions in epithelia.

Authors:  Peying Fong
Journal:  Biophys Rev       Date:  2012-02-15

Review 3.  Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor?

Authors:  E K Schneider; F Reyes-Ortega; J Li; T Velkov
Journal:  Clin Pharmacol Ther       Date:  2016-11-23       Impact factor: 6.875

Review 4.  Cystic fibrosis transmembrane regulator correctors and potentiators.

Authors:  Steven M Rowe; Alan S Verkman
Journal:  Cold Spring Harb Perspect Med       Date:  2013-07-01       Impact factor: 6.915

Review 5.  The cystic fibrosis transmembrane conductance regulator (CFTR) and its stability.

Authors:  Xin Meng; Jack Clews; Vasileios Kargas; Xiaomeng Wang; Robert C Ford
Journal:  Cell Mol Life Sci       Date:  2016-10-12       Impact factor: 9.261

Review 6.  Recent Progress in CFTR Interactome Mapping and Its Importance for Cystic Fibrosis.

Authors:  Sang Hyun Lim; Elizabeth-Ann Legere; Jamie Snider; Igor Stagljar
Journal:  Front Pharmacol       Date:  2018-01-17       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.